AstraZeneca buys cell therapy biotech in up to $1bn deal
[ad_1] Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca has struck a
AstraZeneca to buy EsoBiotec for up to $1 billion
[ad_1] AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion to further boost its cancer capabilities.
